Vaccines and Related Biological Products Advisory Committee
March 6 - March 7
On March 6, 2019, under Topic I, the Center for Biologics Evaluation and
Research’s (CBER) VRBPAC will meet in open session to discuss and make recommendations
on the selection of strains to be included in the influenza virus vaccines for the 2019 to 2020
influenza season. Also on March 6, 2019, under Topic II, the committee will meet in open
session to hear an overview of the research programs in the Laboratory of Immunoregulation
(LIR) and the Laboratory of Retroviruses (LR), Division of Viral Products, Office of Vaccines
Research and Review, CBER, FDA.
On March 7, 2019, under Topic III, the committee will meet in open session to discuss
and make recommendations on the safety and effectiveness of Dengue Tetravalent Vaccine
(Live, Attenuated) (DENGVAXIA) manufactured by Sanofi Pasteur.